1. Introduction {#sec1}
===============

Obesity is commonly associated with the development of type 2 diabetes mellitus (T2DM) \[[@B1]\]. However, the occurrence of diabetic complications in obese subjects is highly variable. In fact, epidemiological data have indicated that \~30% of the obese population is classified as *metabolically healthy but obese* (MHO) \[[@B2], [@B3]\], which is characterized by normal insulin sensitivity and inflammatory profile regardless of excess body fat \[[@B4], [@B5]\]. Alternatively, there is a subgroup of normal weight subjects that exhibit metabolic dysfunction without increased adiposity \[[@B6], [@B7]\]. As such, the underlying factors involved in the development of obesity-related disease are poorly understood.

Fat cell recruitment is a coordinately regulated process that involves activation of proadipogenic transcription factors, including peroxisome proliferator-activated receptor-*γ* (PPAR*γ*) and CCAAT-enhancer-binding protein-*α* (C/EBP*α*) \[[@B8], [@B9]\], as well as inhibition of antiadipogenic signals, including the canonical Wnt/*β*-catenin pathway \[[@B8], [@B10]\]. Thiazolidinediones (TZDs) represent a class of antidiabetic drugs that function through regulation of these pro- and antiadipogenic pathways \[[@B11], [@B12]\]. Similarly, high fat feeding is reported to enhance fat cell recruitment through activation and repression of PPAR*γ* and Wnt signaling, respectively \[[@B13], [@B14]\]. However, the ability to effectively induce adipogenesis with these mechanisms is markedly diminished with aging \[[@B15], [@B16]\]. This finding is supported by a stabilization of total fat cell number in older adults, irrespective of fluctuations with body weight \[[@B17]\]. In contrast, energy surplus during early maturation and young adulthood is commonly associated with morphological adaptations to both adipocyte size and number \[[@B18], [@B19]\].

The link between AT morphology and metabolic dysfunction has been investigated using a variety of preclinical models \[[@B20]--[@B22]\]. In particular, the Obese Zucker (OZR) and Zucker Diabetic Fatty (ZDF) rats are commonly used as a monogenic rodent model of obesity-related disease \[[@B23]\]. These rodents exhibit severe hyperphagia due to recessive homozygous mutation in the leptin receptor (*fa*). However, this mutation also represents a major limitation of these models as defects with leptin signaling are shown to directly impair adipogenic programming \[[@B24]\]. Consequently, morphological changes in AT of these rodents may not accurately reflect the pathophysiology of human obesity.

In light of such issues, the Zucker Diabetic Sprague Dawley/PreClinOmics (ZDSD/Pco) rat was developed. The ZDSD rat was generated by cross-breeding diet-induced obese (DIO) rats derived from the Charles River Laboratory: CD (Sprague Dawley-derived) strain with lean ZDF^*fa*/−^ rats. Selective inbreeding produced animals with a predisposition to DIO and potential to develop overt diabetes between 15 and 21 weeks of age with nutritional intervention \[[@B25]\]. In addition, these rodents display intact leptin signaling, as well as a more modest accumulation of body fat---approximately three times lower compared to OZR and ZDF rats. Therefore, our objective of this study was to use the ZDSD rat to determine the age-related effects of high-fat feeding on AT morphology on metabolic profile.

2. Methods and Procedures {#sec2}
=========================

2.1. Animals, Diets, and Experimental Design {#sec2.1}
--------------------------------------------

All experiments were conducted on male ZDSD/Pco rats (*N* = 24; PreClinOmics, Indianapolis, IN, USA). Animals were given unlimited access to standard low-fat diet ((LFD) Purina 5008; 16.7% kcal fat) postweaning (i.e., 21--28 d after parturition) and then provided high fat diet ((HFD) Research Diets, Inc. D12468; 47.7% kcal fat) beginning at either 63 d, 84 d, or 112 d until termination (i.e., 126 d after parturition). Additionally, a group of ZDSD rats were maintained on LFD for the duration of study. Early adulthood was classified as 63 d after parturition based on Hughes and Tanner \[[@B26]\]. All animals were housed under standard laboratory conditions with a 12 : 12 h light-dark cycle and a controlled room temperature (20-21°C). At 126 d after parturition, rats were fasted overnight and euthanized by CO~2~ asphyxiation. Serum and tissues were then collected, snap frozen in liquid nitrogen, and stored at −80°C for subsequent analysis. AT from the subcutaneous depot was collected from the dorsal scapular region. The protocol and all procedures were approved by the Institutional Animal Care and Use Committee of PreClinOmics and Southern Illinois University, Carbondale, IL, USA.

2.2. Anthropometric and Biochemical Measurements {#sec2.2}
------------------------------------------------

Body composition (EchoMRI-700 Bioanalyzer, Echo Medical Systems, LLC) and blood glucose (Glucometer Elite, Mishawaka, IN, USA) were measured weekly. At termination, total serum cholesterol and triacylglyceride (TAG) were analyzed on a Beckman CX4 clinical analyzer with standard Beckman chemistries. Nonesterified fatty acids (NEFAs) were measured using an NEFA kit (Wako Chemicals, Richmond, VA, USA). Serum C-reactive protein (CRP), serum amyloid P (SAP), and IL-8 were all determined with appropriate assays (ALPCO Diagnostics, Salem, NH, USA).

2.3. NF*κ*B p65 DNA Binding Activity {#sec2.3}
------------------------------------

Nuclear protein was extracted from epididymal and subcutaneous AT (Nuclear Extraction Kit, Cayman Chemical, Ann Arbor, MI, USA). NF*κ*B p65 DNA binding activity was then determined with an enzyme-linked immunosorbent assay (Cayman Chemical). Briefly, a specific double-stranded DNA sequence containing the NF*κ*B response element was immobilized onto the bottom of wells of a 96-well plate. NF*κ*B p65 sequestered from the nuclear extract was detected by addition of a specific primary antibody directed against NF*κ*B p65. A secondary antibody conjugated to horseradish peroxidase was added to provide a sensitive colorimetric readout at 450 nm.

2.4. Gene Expression Analysis {#sec2.4}
-----------------------------

Total RNA was extracted from epidydimal and subcutaneous AT using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and RNeasy mini columns (QIAGEN Inc., Valencia, CA, USA) according to the manufacturer\'s instructions. Purified mRNA was reversely transcribed into cDNA using RT^2^ PCR Array First Strand Kit (SABiosciences, Frederick, MD, USA) and immediately assayed for transcript abundance with customized RT^2^ Profiler PCR Arrays (SABiosciences) using gene-specific primers (proprietary primers, sequence not disclosed). cDNA was diluted into RT^2^ SYBR Green Master Mix (SABiosciences), and quantitative real time PCR was performed using a MyiQ Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Real-time PCRs were performed as follows: melting for 10 min at 95* *°C, 40 cycles of two-step PCR including melting for 15 sec at 95* *°C, and annealing for 1 min at 60* *°C. All cycle threshold (Ct) values of \>35.0 were considered noncycling and removed from analysis. The raw data were analyzed using the ΔΔCt method following the manufacturer\'s instructions \[[@B27]\]. Data were presented as fold change relative to LFD treatment group.

2.5. Histological Analysis {#sec2.5}
--------------------------

Subcutaneous and epidydimal AT was paraffin embedded and stained with hematoxylin and eosin. Morphological analysis was performed using an Olympus BX40 microscope (Olympus America Inc., Center Valley, PA, USA) in conjunction with Image-Pro Plus 5.1 (Media Cybernetics Inc., Bethesda, MD, USA) and Photoshop Extended CS4 Medical Analysis package (Adobe Systems Inc., San Jose, CA, USA). For the quantitation of number and size of adipocytes, the sectional areas of epididymal and subcutaneous AT in the hematoxylin- and eosin-stained preparations were analyzed with Leica QWin Standard software (Leica Microsystems Imaging Solutions, Cambridge, UK) as previously described \[[@B20]\].

2.6. Statistical Analysis {#sec2.6}
-------------------------

Data were tested for normality and analyzed using the mixed-model analysis with Bonferroni adjustment (SAS Institute Inc., Cary, NC, USA). Values are means ± standard error of mean (SEM). Post hoc comparisons were made using the least significant means (LSMEANS) separation with the PDIFF procedure. Differences among LSMEANS were considered significant at *P* \< 0.05, and trends are noted when *P* \< 0.10. This standard analysis was performed for all experiments and aims, unless otherwise specified.

3. Results {#sec3}
==========

3.1. Body Composition and AT Morphology {#sec3.1}
---------------------------------------

In this experiment, administration of HFD at 63 d after parturition (i.e., early adulthood) was associated with distinct changes in body composition without significant differences in overall body weight ([Figure 1](#fig1){ref-type="fig"}). At 126 d after parturition, adiposity was 8.2% greater, whereas lean mass was 6.7% lower with HFD at 63 d versus 84 or 112 d after parturition ([Table 1](#tab1){ref-type="table"}, *P* \< 0.05). Furthermore, we showed that changes in body composition were associated with modifications to AT morphology. Specifically, the mean adipocyte size and number were over 20% and 50% greater with HFD at 63 d after parturition versus all treatment groups ([Table 1](#tab1){ref-type="table"}, *P* \< 0.05).

3.2. Adipogenic Programming {#sec3.2}
---------------------------

To identify potential signaling mechanisms associated with the observed morphological changes in AT, we examined mRNA abundance of several key adipogenic regulators in epidydimal and subcutaneous depots. We observed no marked difference in PPAR*γ* or C/EBP*α* transcript at 126 d after parturition ([Table 2](#tab2){ref-type="table"}). Alternatively, transcript abundance of several genes associated with the canonical Wnt signaling network was significantly lower with HFD at 63 d after parturition ([Table 2](#tab2){ref-type="table"}, *P* \< 0.05). More specifically, the canonical Wnt ligands Wnt1, Wnt3a, and Wnt10b were all downregulated in subcutaneous and epidydimal AT with HFD at 63 d versus 112 d after parturition (*P* \< 0.05). Expression of Wnt1 and Wnt3a was also lower in subcutaneous AT with initiation of HFD at 63 d versus 84 d after parturition (*P* \< 0.05). Furthermore, transcript abundance of the canonical Wnt receptors Fzd1, Fzd2, and Fzd5 was lower in AT with initiation of high fat feeding at 63 d versus 112 d (*P* \< 0.05). There were no significant differences in expression of the intracellular Wnt signaling intermediates GSK3*β*, *β*-catenin, or TCF/LEF in subcutaneous AT. Alternatively, transcript abundance of GSK3*β* and *β*-catenin was lower in epididymal AT with HFD at 63 d versus 112 d after parturition (*P* \< 0.05).

3.3. AT Inflammation {#sec3.3}
--------------------

AT dysfunction is associated with a proinflammatory state that contributes to an induction of canonical Wnt/*β*-catenin signaling \[[@B28]\]. Herein, NF*κ*B p65 DNA binding activity was 10--20% lower in epididymal AT and 40--45% lower in subcutaneous AT in rodents fed HFD beginning at 63 d versus 84 and 112 d after parturition ([Figure 2](#fig2){ref-type="fig"}, *P* \< 0.05). The mRNA abundance of NF*κ*B was also moderately lower in epididymal AT with HFD at 63 d versus 112 d ([Table 3](#tab3){ref-type="table"}, *P* \< 0.05). Moreover, the expression of downstream targets of NF*κ*B was lower in AT with HFD at 63 d versus 112 d ([Table 3](#tab3){ref-type="table"}). In particular, transcript abundance of the acute phase proteins CRP and SAP was lower with HFD at 63 d versus 112 d after parturition (*P* \< 0.05). Similarly, MCP1 transcript abundance was markedly lower in subcutaneous and epididymal AT with HFD at 63 versus 112 d (*P* \< 0.05). The mRNA abundance of the macrophage-specific marker F4/80 was also lower with HFD at 63 d versus 112 d after parturition (*P* \< 0.05).

3.4. Metabolic Profile {#sec3.4}
----------------------

As discussed previously, not all obese individuals exhibit metabolic dysfunction \[[@B3]--[@B5], [@B29]\]. Consistent with a benign obesity phenotype, we showed that blood glucose concentration was 60--65% lower with HFD at 63 d versus 84 or 112 d after parturition ([Table 4](#tab4){ref-type="table"}, *P* \< 0.0001). Furthermore, several markers of dyslipidemia were lower with initiation of high-fat feeding in early adulthood ([Table 4](#tab4){ref-type="table"}). In particular, serum cholesterol, NEFA, and TAG concentrations were 15%, 50%, and 60% lower with HFD at 63 d versus 84 or 112 d after parturition (*P* \< 0.05). Moreover, the serum inflammatory markers SAP, CRP, and IL-8 were 7 to 20%, 21 to 60%, and 55 to 62% lower with high fat feeding at 63 d versus 84 or 112 d after parturition ([Table 4](#tab4){ref-type="table"}, *P* \< 0.05).

4. Discussion {#sec4}
=============

In this study, we show that initiation of high fat feeding in early adulthood was associated with greater preservation of local and systemic glucose, lipid, and inflammatory homeostasis compared to ZDSD rats fed HFD beginning at 84 or 112 d after parturition. Although the specific mechanisms are not fully elucidated, high fat feeding in early adulthood increased both adipocyte size and number, which was associated with a marked reduction in antiadipogenic Wnt signaling intermediates. Collectively, our data indicate that exposure to HFD during early adulthood modifies AT morphology and protects against obesity-related disease.

The concept of a "metabolically healthy but obese" (MHO) phenotype has been recognized for several decades \[[@B30]\]. Although the specific mechanisms are unclear, it is now suggested that AT plasticity may be a primary determinant of obesity phenotype \[[@B31]\]. Consistent with this hypothesis, our data show that increased fat cell size and number were associated with maintenance of metabolic homeostasis in ZDSD rats. Kim et al. \[[@B32]\] similarly reported that fat cell hyperplasia was a central mitigator of metabolic dysfunction in obese transgenic mice. Additionally, synthetic PPAR*γ* agonists are reported to enhance glucose and lipid metabolism through recruitment of adipocytes or dedifferentiation of mature fat cells \[[@B33], [@B34]\]. We also cannot exclude the potential protective impact of a modest expansion in fat cell volume. For instance, enlargement of subcutaneous fat cells was associated with greater insulin sensitivity in patients treated with pioglitazone \[[@B35]\], and a greater number of small adipose cells in obese individuals have been associated with impaired insulin sensitivity and may indicate impaired adipogenesis \[[@B36]\]. It is therefore likely that both adipocyte hyperplasia and hypertrophy are important for preservation of metabolic homeostasis in obesity.

Age-related impairment of fat cell recruitment is also implicated as a major determinant of obesity phenotype \[[@B37], [@B38]\]. Previous work \[[@B39]--[@B41]\] has suggested that adipocyte number is influenced primarily in infancy and childhood. More recently, Spalding and colleagues \[[@B17]\] used integration of 14 C (from nuclear bomb tests) in genomic DNA to demonstrate that adipocyte number becomes relatively stable in late adulthood, irrespective of fluctuations in fat mass. In this study, our data indicate that early adulthood may also be an important phase for regulation of fat cell recruitment. These data are also consistent with a previous study showing diet-induced adipocyte hyperplasia in rodents at approximately 55 d after parturition \[[@B42]\]. As such, early adulthood represents an important phase for diet-induced changes in AT morphology.

The reduction in fat cell recruitment during late adulthood tightly corresponds with a decrease in expression or activation of PPAR*γ* \[[@B15], [@B43]\]. It is well recognized that PPAR*γ* acts as a master regulator for adipogenesis. As such, nearly all aspects of fat cell morphology are regulated by agonists and antagonists for this transcription factor \[[@B8], [@B9]\]. In our study, we observed no differences in PPAR*γ* mRNA abundance at 126 d after parturition. This may indicate that any changes in expression or activation occurred prior to termination. Consistent with this observation, previous studies have shown that induction of PPAR*γ* is markedly reduced in aged rodents \[[@B15], [@B16]\]. Although it is also possible that initiation of high-fat feeding prior to 63 d after parturition may have a more substantial impact on AT morphology, our data indicate regulation of PPAR*γ* in early adulthood is likely responsible for the increase in fat cell number.

Previous studies \[[@B44], [@B45]\] have shown that activation of canonical Wnt/*β*-catenin signaling augments adipocyte hypertrophy by antagonism of PPAR*γ* \[[@B44], [@B45]\]. Gustafson and Smith \[[@B34]\] suggested that activation of the Wnt signaling cascade exacerbated obesity-associated dysfunction through dedifferentiation of mature adipocytes. Consistent with these data, we showed that increased adipocyte number was associated with lower expression of the Wnt ligands, receptors, and signaling intermediates. Although the relationship between Wnt signaling and impaired adipogenesis has become evident, it remains unclear how this pathway may be differentially regulated in obesity. It was previously reported that increased inflammation inhibits adipocyte differentiation \[[@B46]\]. However, recent work suggested that increased TNF*α* and IL-6 enhanced fat cell hypertrophy through stimulation of the canonical Wnt/*β*-catenin pathway \[[@B28]\]. Herein, we similarly showed that reduced Wnt signaling was associated with lower NF*κ*B activation and proinflammatory gene expression in AT of obese ZDSD rats. Additional studies will need to determine whether dietary regulation of adipocyte recruitment in early adolescence is due to modification of Wnt/*β*-catenin signaling or inflammatory status.

In summary, we have used a novel physiologically relevant preclinical model to determine how obesity phenotype is influenced by initiation of high-fat feeding at different phases of adulthood. Our findings suggest that administration of HFD in early adulthood maintained glucose, lipid, and inflammatory profiles through expansion of fat cell size and number. Although there were no changes in proadipogenic factors, we observed a marked reduction in antiadipogenic canonical Wnt/*β*-catenin signaling intermediates. Collectively, these data establish that dietary regulation of adipogenesis in early adulthood may help preserve metabolic homeostasis in obesity.
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![*Age-related effects of high-fat feeding on body weight and composition in male ZDSD rats*. Data were collected at two-week intervals from 70 d to 126 d after parturition. All graphed values represent means ± SE. (a) Body weight expressed as grams. (b) Total fat mass expressed as percent of body weight. (c) Total lean mass expressed as percent of body weight.](ISRN.OBESITY2013-584547.001){#fig1}

![*Age-related effects of high-fat feeding on NF*κ*B p65 DNA binding activity in epididymal and subcutaneous AT of male ZDSD rats*. NF*κ*B p65 DNA binding activity was determined by an ELISA, according to the manufacturer\'s instructions (Cayman Chemical). Displayed values represent LSMEANS ± SE. Different letters represent significant differences between groups (*P* \< 0.05).](ISRN.OBESITY2013-584547.002){#fig2}

###### 

Body composition and AT morphology in ZDSD rats fed HFD beginning at 63, 84, and 112 d after parturition.

                              LFD               HFD 63 d          HFD 84 d         HFD 112 d
  --------------------------- ----------------- ----------------- ---------------- ----------------
  Body weight (g)             531 ± 27.4        514 ± 27.4        454 ± 27.4       480 ± 27.4
   Fat mass^†^                14.8 ± 2.54^a^    23.0 ± 2.54^b^    14.8 ± 2.54^a^   14.3 ± 2.54^a^
   Lean mass^†^               70.2 ± 1.79^a^    62.5 ± 1.79^b^    69.3 ± 1.79^a^   69.2 ± 1.79^a^
   Water mass^†^              59.2 ± 2.35       55.3 ± 2.35       58.0 ± 2.35      57.9 ± 2.35
  Subcutaneous adipocyte^‡^                                                         
   Area (*μ*m^2^)             8318 ± 807^ab^    10009 ± 931^b^    6360 ± 807^a^    6869 ± 807^a^
   Number                     371 ± 76.7^a^     647 ± 88.5^b^     288 ± 76.7^a^    266 ± 76.7^a^
  Epididymaladipocyte^‡^                                                            
   Adipocyte area (*μ*m^2^)   9368 ± 1131^ab^   11356 ± 1131^b^   8530 ± 1131^a^   8520 ± 1131^a^
   Number                     149 ± 40.3^a^     270 ± 40.3^b^     137 ± 43.3^a^    128 ± 43.3^a^

\*Letters represent significant differences among means as determined by post hoc comparison (*P* \< 0.05).

^†^Data presented as percent of total body weight.

^‡^Determined by analysis of fixed area on H & E stained slides.

###### 

Transcript abundance of Wnt signaling intermediates in AT depots of ZDSD rats fed HFD beginning at 63, 84, or 112 d after parturition.

                                              Subcutaneous              Epididymal                        
  ------------------------------------------- -------------- ---------- ------------ --------- ---------- ----------
  Adipogenic transcription factors                                                                        
                                                                                                          
  PPAR*γ*                                     1.18           1.56       1.23         1.17      1.20       1.43
  C/EBP*α*                                    1.14           1.18       1.15         0.93      1.20       1.26
                                                                                                          
  Wnt ligands                                                                                             
                                                                                                          
  Wnt1                                        0.33^a^        0.82^b^    0.88^b^      0.88^a^   1.56^a^    5.36^b^
  Wnt3a                                       0.92^a^        1.95^b^    3.02^c^      1.12^a^   1.32^a^    3.92^b^
  Wnt10b                                      0.62^a^        0.44^a^    2.97^b^      0.78^a^   0.47^a^    3.94^b^
                                                                                                          
  Extracellular Wnt receptors                                                                             
                                                                                                          
  Fzd1                                        0.93^a^        1.17^ab^   1.93^b^      1.29      1.45       1.44
  Fzd2                                        0.53^a^        1.00^ab^   1.82^b^      2.69^a^   2.51^a^    10.74^b^
  Fzd5                                        1.06^a^        1.46^ab^   1.95^b^      0.62^a^   1.08^ab^   1.38^b^
                                                                                                          
  Intracellular Wnt signaling intermediates                                                               
                                                                                                          
  Gsk3*β*                                     1.02           1.43       0.89         4.39^a^   4.17^a^    8.20^b^
  *β*-catenin                                 1.09           1.32       1.34         2.44^a^   2.41^a^    6.44^b^
  TCF/LEF                                     0.62           0.82       0.78         0.85      1.28       1.27

\*Data are expressed as fold change relative to animals fed LFD. Letters represent significant difference among treatment groups as determined by comparison of normalized Ct values (target Ct-housekeeping Ct) with paired *t*-test.

###### 

Transcript abundance of proinflammatory factors in AT depots of ZDSD rats fed HFD beginning at 63, 84, or 112 d after parturition.

           Subcutaneous   Epididymal                                  
  -------- -------------- ------------ --------- --------- ---------- ----------
  CRP      0.86^a^        1.40^ab^     3.22^b^   1.73^a^   1.80^a^    6.36^b^
  SAP      0.97^a^        1.33^ab^     2.06^b^   2.25^a^   2.74^a^    7.50^b^
  MCP1     0.83^a^        2.02^b^      2.45^b^   4.31^a^   4.36^a^    14.00^b^
  NF*κ*B   0.78           1.24         1.36      2.24^a^   2.66^a^    5.96^b^
  F4/80    0.91^a^        1.13^a^      2.46^b^   0.54^a^   1.40^ab^   1.95^b^

\*Data are expressed as fold change relative to animals fed LFD. Letters represent significant difference among treatment groups as determined by comparison of normalized Ct values (target Ct-housekeeping Ct) with paired *t*-test.

###### 

Systemic metabolic profile in ZDSD rats fed HFD beginning at 63, 84, or 112 d after parturition.

                         LFD               HFD 63 d         HFD 84 d          HFD 112 d
  ---------------------- ----------------- ---------------- ----------------- -----------------
  Glucose (mmol/L)       10.33 ± 3.52^a^   8.94 ± 3.52^a^   24.27 ± 3.52^b^   26.02 ± 3.52^b^
  TAG (mmol/L)           4.88 ± 7.50^a^    8.19 ± 7.50^a^   33.56 ± 7.50^b^   22.85 ± 7.50^b^
  Cholesterol (mmol/L)   4.41 ± 0.10^a^    3.32 ± 0.10^b^   3.84 ± 0.10^c^    4.02 ± 0.10^c^
  NEFA (mEq/L)           0.52 ± 0.06^a^    0.27 ± 0.06^b^   0.54 ± 0.06^c^    0.61 ± 0.06^c^
  CRP (nmol/L)           16.22 ± 1.41^a^   4.39 ± 1.41^b^   12.85 ± 1.41^a^   3.60 ± 1.41^b^
  SAP (*μ*mol/L)         2.79 ± 0.13^a^    1.58 ± 0.13^c^   2.00 ± 0.13^ab^   1.71 ± 0.13^bc^
  IL-8 (pmol/L)          84.2 ± 17.5^a^    28.2 ± 17.5^b^   62.7 ± 17.5^ab^   74.9 ± 17.5^a^

\*Letters represent significant differences among means as determined by post hoc comparison.
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